NAT2 and urinary bladder cancer: Epidemiological studies and genome-wide association (GWA) studies in Europe consistently reported higher risk of bladder cancer associated with the SNP-inferred NAT2 slow acetylation status among ever smokers [9–12, 23, 40, 41].